Iambic Files for a US IPO
Reuters reports that AI-assisted drug developer Iambic Therapeutics filed for a Nasdaq listing under IAM without yet setting the offering size or price. Iambic Therapeutics, a San Diego biotechnology company founded in 2019, is seeking access to public markets. The company uses machine learning in small-molecule drug discovery and is developing IAM1363, an experimental treatment in early clinical testing for solid tumors. Its filing arrives while investors are selectively returning to biotechnology listings. ...